Novo Nordisk Partners with Hims on GLP-1 Distribution; BMS Wins Sotyktu PsA Approval

Novo Nordisk just stopped fighting the telehealth compounders — and started partnering with them. They announced a deal with Hims & Hers this morning to sell branded GLP-1s together.

And Bristol Myers stacked two wins in a single day — Sotyktu gets its psoriatic arthritis label, and their next-gen CELMoD hit in Phase 3. Busy Monday. Let's get into it.

Welcome to The Pharma Closeout for Monday, March 9th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Here's what actually happened this morning. Novo Nordisk and Hims & Hers announced a partnership that ends their legal dispute over compounded GLP-1 medications. Hims agrees to limit compounding. In exchange, they become a distribution channel for Novo's branded drugs — Ozempic, Wegovy — through their telehealth platform.

So Novo looked at the lawsuit, looked at the telehealth market trajectory, and decided co-optation beats litigation.

Exactly right. If patients want GLP-1s through an app on their phone, Novo would rather they get the branded product than a compounded version Novo can't control and doesn't profit from.

I'm skeptical about what "limit compounding" means in practice, though. The press release is vague. If Hims retains any compounding capability — even at reduced volume — that's a very different agreement than a complete exit from that business. And the economics of compounded semaglutide are attractive enough that I'd be surprised if they walk away entirely.

No financial terms disclosed, so we don't know about revenue sharing, volume commitments, pricing concessions. But the strategic signal is clear: the GLP-1 incumbents aren't just defending molecules anymore. They're competing for the distribution model that reaches patients fastest.

Which puts pressure on Lilly. If Novo's in the telehealth channel, Lilly has to decide whether to follow or cede that access point. And the compounding shops without a partnership path forward? They're getting squeezed from both directions now — regulatory heat and competitive pressure from the brand owners themselves.

The distribution wars are entering a new phase. It's no longer branded versus compounded — it's about who controls patient access. Today, Novo made a move to own more of that layer.

Speaking of access plays — there was another deal today that fits the same pattern.

Universal Health Services acquiring Talkspace for 835 million dollars. UHS runs hospitals and behavioral health facilities. Talkspace is a digital mental health platform with about 1.2 million members. Do the math — that's roughly 700 dollars per member.

Traditional healthcare buying its way into telehealth rather than building it. The behavioral health M&A thesis in one transaction.

Pipeline news came fast today. Bristol Myers announced their second-generation CELMoD hit its primary endpoint in Phase 3 for blood cancer. Same cereblon pathway as Revlimid, next-generation molecule. No specific efficacy numbers yet, but with Revlimid revenues declining post-LOE, this franchise has to work. It's not optional for their oncology outlook.

Xenon also reported Phase 3 success in epilepsy — their first potential commercial product. Analysts are using the word "blockbuster." Competitive space, but real unmet need in treatment-resistant populations.

And Dianthus Therapeutics announced a proposed 400 million dollar public offering. Complement-mediated autoimmune diseases. A raise that size at this stage tells you they're funding through pivotal readouts — the capital is being raised now for decisions that come later.

I want to stay with Bristol Myers for a moment, because they had a regulatory win to match the clinical one.

The Sotyktu approval.

FDA granted the psoriatic arthritis indication. We flagged this PDUFA last week — it landed as expected. Sotyktu now has both plaque psoriasis and PsA on the label, which puts it directly against Skyrizi and Tremfya in the inflammatory space. The TYK2 mechanism finally has a commercial runway beyond dermatology.

That label expansion was what the sales team needed. Dermatology-only was limiting the prescriber base and the call points.

Now, the less positive news. Incyte received a Complete Response Letter — but not because of their drug. The issue is manufacturing problems at Novo Nordisk's Indiana fill-finish facility. Incyte is now the third company to get a CRL tied to that same plant.

Third company. Same facility.

Pure CMC issue. Nothing wrong with the PD-1 molecule itself. But this delays their checkpoint inhibitor launch by potentially 6 to 12 months while they find remediation or an alternative site. That's a real competitive setback in a crowded space.

CDMO concentration risk, playing out in real time. Novo's facility produces third-party drugs, and quality problems there are cascading across multiple partners.

One more — Ipsen is voluntarily withdrawing Tazverik from the market. The EZH2 inhibitor they got through the Epizyme acquisition. The confirmatory study showed increased secondary malignancies. New cancers in treated patients. You can't label around that. You can't restrict your way out of it.

Accelerated approval giveth, confirmatory data taketh away. When confirmation fails on safety rather than efficacy, there's no salvage path.

Two calendar items before we close.

Mineralys Therapeutics got FDA acceptance for their lorundrostat NDA in hypertension. PDUFA date is December 22nd. Aldosterone synthase inhibitor — different mechanism than the receptor blockers. Novel target, long runway to the decision.

And GSK's linerixibat PDUFA for cholestatic pruritus sits on March 24th. Two weeks out. If you're tracking the liver disease itch space — and I know some of you are — that's your next decision point.

Sector context worth noting: healthcare is up 3.4 percent year-to-date, outperforming the S&P. Drug manufacturers specifically? Up 16 percent YTD. The large-cap pharma names are catching a bid right now.

That backdrop matters for how the market digests news like the Novo-Hims partnership. When the sector's working, strategic pivots get rewarded.

That is your Pharma Closeout for Monday, March 9th — Novo rewriting the GLP-1 distribution playbook, Bristol Myers stacking a label expansion and a Phase 3 win on the same day, and Novo's Indiana plant still causing headaches for partners who didn't see the CMC risk coming. If this helps you stay across the space, follow us wherever you listen and drop a rating. We're back tomorrow.

Plenty more coming this week. Enjoy your evening — see you tomorrow.